|
犬尿氨酸是一种非蛋白质性氨基酸，在色氨酸降解过程中作为代谢中间体产生[1-5]。色氨酸的降解是由诱导型酶吲哚胺-2，3-双加氧酶（IDO）催化的。产品为犬尿氨酸[4，6-8]。细胞因子，特别是干扰素γ[5，9，10]，会影响IDO的活性，因此犬尿氨酸途径与免疫系统密切相关[9，11]。犬尿氨酸可以进一步转化为具有神经保护作用的犬尿氨酸酯，也可以转化为具有神经毒性的喹啉酸[6，11]。 
LDN Labor Diagnostika Nord-犬尿氨酸ELISA（BA E-2200R）： 名称：犬尿氨酸酶联免疫吸附试验（ELISA） 描述：用于血清和EDTA血浆样本中L-犬尿氨酸的定量酶免疫测定。 设计：通用的样品准备。液相衍生化（96孔反应板）。12×8可分离式微孔板。6个标准品。2个对照品。即用型。 样品体积： 10微升血清或血浆 总测定时间：样品准备和酰化1小时30分钟；ELISA过夜，2次各30分钟 标准范围：0/100 - 10,000纳克/毫升 灵敏度：45.7纳克/毫升 储存：2 - 8摄氏度 试剂盒：96次测定 优点： - 广泛的标准范围 - 易于操作 - 高分析特异性 - 与高度复杂的XLC-MS/MS方法有极好的相关性 - 欧盟CE认证：是 LDN Labor Diagnostika Nord-犬尿氨酸ELISA预期用途和原理： 酶免疫测定法用于定量测定血清和EDTA血浆样品中的L-犬尿蛋白，以评估L-犬尿素稳态。在酰化过程中，犬尿蛋白在37°C下被激活，随后与蛋白质偶联。随后的竞争ELISA使用微量滴定板形式。抗原与微量滴定板的固相结合。酰化标准品、对照品和样品的分析物浓度与固定数量的抗体结合位点的固相结合分析物浓度相匹配。在系统处于平衡状态后，通过洗涤除去游离抗原和游离抗原-抗体复合物。通过偶联TMB作为底物的抗兔IgG过氧化物酶检测与固相结合的抗体，从而产生显色反应。在450nm的波长下监测反应。通过将未知样品的吸收与用已知标准浓度制备的参考曲线进行比较来实现未知样品的定量。建议手动处理ELISA。自动实验室设备的使用由用户负责。本产品不用于临床诊断。 LDN Labor Diagnostika Nord-犬尿氨酸ELISA文献参考： 1.Konishi,M.,et al.,Impact of Plasma Kynurenine Level on Functional Capacity and Outcome in Heart Failure-Results From Studies Investigating Co-morbidities Aggravating Heart Failure (SICA- HF).Circ ],2016.81(1):p.52-61. 2. Li,H.,et al.,Metabolomic adaptations and correlates of Sorvival to immune checkpoint blockade.Nat Commun,2019.10(1):p.4346. 3. Metcalfe,A.J.,et al.,Acute and chronic effects of exercise on the kynurenine pathway in humans-A brief review and future perspectives.Physiol Behav,2018.194:p.583-587. 4.Zinellu,A.,et al.,Impact of cholesterol loweriog treatment on plasma kynurenine and tryptophanconcentrations in chronic kidney disease:celationship with oxidative stress improvement.NutrMetab Cardiovasc Dis,2015.25(2):p.153-9. 5.de Jong,W.H.,et al.,Plasma tryptophan,kynurenine and 3-hydroxykynurenine measurementusing automated on-line solid-phase extraction HPLC-tandem mass spectrometry.]ChromatogrB Analyt Technol Biomed Life Sc,2009.877(7):p.603-9. 6.Barone,P.,The Yin'and the Yang'of the kynurenine pathway:excitotoxicity and neuroprotectionimbalance in stress-induced disorders.Behav Pharmacol,2019.30(2 and 3-Spec Issue):p.163-186. 7.Keegan,M.R.,et al.ryptophan metabolism and its relationship with central nervous systemtoxicity in people liing with HIV switching from efavirenz to dolutegravir.]Neurovirol,2019.25(1):p.85-90 8.Kim,Y.K.and S.W.Jeon,Neuroinflammation and the Immune-Kynurenine Pathway in AnxietyDisorders.Curr Neuropharmacol,2018.16(5):p.574-582. 9.Lim,C.Ket al.,Involvement of the kynurenine pathway in the pathogenesis of Parkinson'sdisease.Prog Neurobiol,2017.155:p.76-95. 10.StraSser,B.,et al.,Kynurenine pathway metabolism and immune activation:Peripheralmeasurements in psychiatric and co-morbid conditions.Neuropharmacology,2017.112(Pt B):p.286-296. 11.Look,M.P.,et al.,Parallel decrease in neurotoxin quinolinic acid and soluble tumor necrosis factorreceptor p75 in serum during highly active antiretroviral therapy of HIV type 1 disease.AIDS ResHum Retroviruses,2000.16(13):p.1215-21.
|
